Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying

Published 18/01/2024, 13:54
© Reuters.  Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying
OPK
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

OPKO Health

  • The Trade: OPKO Health, Inc. (NASDAQ: OPK) Vice Chairman and CTO PH Jane Hsiao acquired a total of 150,000 shares an average price of $0.95. To acquire these shares, it cost around $142,500.
  • What’s Happening: OPKO Health recently priced private offering of $200 million convertible senior notes due 2029.
  • What OPKO Health Does: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs.
BioCorRx
  • The Trade: BioCorRx Inc. (OTC: BICX) Interim President Louis C Lucido acquired a total of 3,126 shares at at an average price of $0.70. To acquire these shares, it cost around $2,188.
  • What’s Happening: The company’s stock fell around 22% over the past month.
  • What BioCorRx Does: BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders.

Coeptis Therapeutics

  • The Trade: Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) CFO Brian Cogley acquired a total of 5,000 shares at an average price of $0.67. The insider spent around $3,350 to buy those shares.
  • What’s Happening: Coeptis Therapeutics recently said that Dave Mehalick, President and CEO, issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.
  • What Coeptis Therapeutics Does: Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
Collective Audience
  • The Trade: Collective Audience, Inc. (NASDAQ: CAUD) CEO Peter Bordes acquired a total of 20,000 shares at an average price of $0.94. The insider spent around $18,800 to buy those shares.
  • What’s Happening: Collective Audience named former Ogilvy and WPP executive, Christopher Andrews, as Chief Operating Officer.
  • What Collective Audience Does: Collective Audience Inc is a provider of e-commerce and digital customer acquisition solutions by simplifying digital advertising.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.